B vitamin
Vitamin B12
Vitamin B12 reaches its plasma peak within 1 hour of intramuscular injection on the US cyanocobalamin label; the app lists its half-life as 144 hours.1
Vitamin B12 after one dose: 50% at ~144 h, 25% at 288 h, 12.5% at 432 h.
Drawn from the half-life in the app's model, ~144 h. The model's figures
- Compound
- Vitamin B12
- Symbol
- B12
- Family
- Supplements
- Parts
- 14
- References
- 10
- Checked
- Last reviewed . Sources are listed below.
Overview
Sources in this part
Vitamin B12 is a cobalt-containing vitamin, and cobalamin is the term for compounds with vitamin B12 activity.2 The US label for cyanocobalamin injection describes a sterile solution for intramuscular or subcutaneous injection.1 The Linus Pauling Institute states that cyanocobalamin is the principal form in oral supplements in the United States, while hydroxycobalamin is used primarily in Europe.2 The US label lists vitamin B12 deficiencies due to malabsorption, including Addisonian (pernicious) anemia, as the indication.1 The UK summary of product characteristics for hydroxocobalamin 1 mg/mL lists Addisonian pernicious anaemia, other macrocytic anaemias associated with vitamin B12 deficiency, and tobacco amblyopia and Leber's optic atrophy.3 The app grades the evidence for vitamin B12 as strong, and its entry notes that route matters more than for almost any other vitamin.
How it works
Sources in this part
In mammals, cobalamin is a cofactor for two enzymes, methionine synthase and L-methylmalonyl-coenzyme A mutase.2 Cyanocobalamin, the form in most supplements, is readily converted in the body to the two coenzyme forms, 5-deoxyadenosylcobalamin and methylcobalamin.2 The US label states that gastrointestinal absorption of vitamin B12 depends on sufficient intrinsic factor and calcium ions, and that intrinsic factor deficiency causes pernicious anemia.1 Vitamin B12 can also be absorbed by passive diffusion, which the Linus Pauling Institute calls very inefficient, with about 1% to 2% of an oral dose absorbed this way.2 The US label states that absorbed vitamin B12 is carried by the binding proteins transcobalamin I and II and that the liver is the main organ for storage.1
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~144 h
- Bioavailability
- 95%
- Typical dose
- 500–1000 mcg
- Route
- IM, SubQ, oral
- Time to peak
- ~1 h
Sources in this part
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~6 days (144 h), modelled as one compartment | No half-life figure appears in the sources read; see What is not known1,3,2 |
| Time to peak | ~1 h | Plasma peak within 1 hour after intramuscular injection of cyanocobalamin (US label)1 |
| Bioavailability | 95% | Injection: "quantitatively and rapidly absorbed" from intramuscular and subcutaneous sites (US label). Oral: approximately 1% of the amount ingested absorbed by simple diffusion (US label); about 1% to 2% of an oral dose absorbed passively (Linus Pauling Institute)1,2 |
| Urinary loss after injection | Not an app figure | 50 to 98% of an injected 100 or 1000 mcg dose may appear in urine within 48 hours, most of it in the first 8 hours (US label)1 |
| Retention after injection | Not an app figure | Hydroxocobalamin is better retained than cyanocobalamin: 90% of a 100 microgram dose and 30% of a 1000 microgram dose retained (UK summary of product characteristics)3 |
| Body stores | Not an app figure | Total body stores can exceed 2,500 μg, with slow daily turnover (Linus Pauling Institute)2 |
The app's figure of 95% bioavailability is the injected value; the US label states that approximately 1% of the total amount ingested is absorbed by simple diffusion and that oral absorption is considered too undependable to rely on in patients with pernicious anemia or other conditions resulting in malabsorption of vitamin B12, and the app's own entry also notes the low oral absorption.1 The US label states that intravenous use results in "even more rapid excretion with little opportunity for liver storage".1
Human studies
The Cochrane review, Kuzminski and OB12 trials below compare oral with injected vitamin B12 in people with low B12; the Eussen trial compared oral doses with one another, and the metformin trial measured vitamin B12 as an outcome of a different drug.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Wang and colleagues, Cochrane Database of Systematic Reviews 20184 | Systematic review of randomised trials; no meta-analysis because of the small number of trials and substantial clinical heterogeneity4 | Three trials, 153 participants (74 oral, 79 intramuscular); mean age 38.6 to 72 years4 | Daily oral doses and intramuscular regimens varied; two trials used 1000 μg/day oral and one used 2000 μg/day; 3 to 4 months4 | Low-quality evidence of no clinically relevant difference in serum B12 at 1000 μg/day oral; a mean difference of 680 pg/mL (95% CI 392.7 to 967.3) favouring oral at 2000 μg/day in one trial; 2 of 30 (6.7%) left the oral arm of one trial early because of adverse events; no trial reported clinical signs and symptoms4 |
| Kuzminski and colleagues, Blood 19985 | Randomised trial, oral against intramuscular cyanocobalamin5 | 38 newly diagnosed cobalamin-deficient patients randomised; 18 evaluable in the oral group and 15 in the parenteral group after 5 were found to have folate deficiency5 | 2 mg oral daily for 120 days against 1 mg intramuscular on days 1, 3, 7, 10, 14, 21, 30, 60 and 905 | Haematological and neurological correction "prompt and indistinguishable between the 2 groups"; at 4 months mean serum cobalamin 1,005 pg/mL oral against 325 pg/mL parenteral5 |
| Eussen and colleagues, Archives of Internal Medicine 20056 | Randomised, parallel-group, double-blind, dose-finding trial of oral cyanocobalamin6 | 120 older people with mild B12 deficiency (serum B12 100 to 300 pmol/L and methylmalonic acid 0.26 μmol/L or greater)6 | Daily oral 2.5, 100, 250, 500 and 1000 μg for 16 weeks6 | Mean reductions in plasma methylmalonic acid of 16%, 16%, 23%, 33% and 33% across the five doses6 |
| Sanz-Cuesta and colleagues, OB12, BMJ Open 20207 | Pragmatic, randomised, non-inferiority, multicentre trial in 22 primary care centres in Madrid, funded by Spanish public bodies7 | 283 patients aged 65 or older with B12 deficiency (140 oral, 143 intramuscular); 229 (80.9%) completed 52 weeks7 | Oral 1 mg/day in weeks 1 to 8, then 1 mg/week; intramuscular 1 mg on alternate days in weeks 1 to 2, weekly in weeks 3 to 8, then monthly; 52 weeks7 | Normal B12 at week 8 in 133 of 140 oral and 129 of 143 intramuscular (intention to treat); at week 52, 73.6% oral against 80.4% intramuscular; oral non-inferiority not met over the full follow-up7 |
| de Jager and colleagues, HOME trial, BMJ 20109 | Multicentre randomised placebo-controlled trial of metformin; vitamin B12 as the outcome9 | 390 people with type 2 diabetes treated with insulin9 | Metformin 850 mg or placebo three times a day for 4.3 years; no vitamin B12 given9 | Vitamin B12 19% lower with metformin than placebo (95% CI −24% to −14%); vitamin B12 deficiency in 19 (9.9%) against 5 (2.7%) at the end9 |
Deeper analysis: the OB12 trial
Sanz-Cuesta and colleagues (the OB12 Group, Madrid primary care) reported the trial in BMJ Open in 2020.7 The registry entry lists the lead sponsor as Gerencia de Atención Primaria, Madrid, with Instituto de Salud Carlos III as a collaborator, a status of COMPLETED, and masking of the outcomes assessor only.8 The registry plans 320 patients (160 in each arm), and the paper reports 283 randomised.7,8 The main outcome was normalisation of serum vitamin B12 (211 pg/mL or higher) at 8, 26 and 52 weeks, with non-inferiority declared if the difference between arms was 10% or less.7 At week 8 the percentage with normal B12 was "well above 90%" in each arm, with a per-protocol difference of -0.7% (133 out of 135 against 129 out of 130; 95% CI -3.2 to 1.8).7 At week 52 the per-protocol difference was -6.3% (103 out of 112 against 115 out of 117; 95% CI -11.9 to -0.1; p=0.025), and the intention-to-treat difference was -6.8% (103 out of 140 against 115 out of 143; 95% CI -16.6 to 2.9; p=0.171).7 The authors conclude that oral administration "was no less effective than IM administration at 8 weeks" and that, although differences were found at week 52, "the probability that the differences were below the non-inferiority threshold was very low".7 Secondary results: 83.4% of patients preferred the oral route, and quality of life and adverse effects were comparable across groups.7 Eleven adverse events were reported, none severe: five (3.57%) in the oral arm and six (4.20%) in the intramuscular arm, and three patients withdrew (one oral, two intramuscular).7 Limitations the authors state include that the design "did not allow for masking the patients to the received treatment", that a placebo-controlled trial was not appropriate on ethical grounds, and that most participants "presented no symptomatology or very low-level symptoms, with no anaemia".7 The sample-size statement lists a statistical power of 60%, and 229 of 283 completed follow-up.7 The authors also state that the sample size reached only 88.4% of the calculated necessary size, which implies that the power of the study was limited, and that at 52 weeks losses were 20% in the oral arm and 18% in the intramuscular arm, several of the oral losses being withdrawals occasioned by not achieving particular levels of vitamin B12.7 Funding came from Spanish public bodies including the Ministerio de Sanidad y Consumo Español and Instituto de Salud Carlos III; the statement says the funders had "no role in the study design, data collection, onsite monitoring, data analysis, data interpretation or writing of the manuscript", and the authors declare no competing interests.7
Deeper analysis: the Cochrane review of oral against intramuscular vitamin B12
Wang and colleagues (Beijing University of Chinese Medicine and collaborators) published the review in the Cochrane Database of Systematic Reviews in 2018, with a latest search date of 17 July 2017.4 It included randomised trials of oral against intramuscular vitamin B12 for deficiency, with serum B12, clinical signs and symptoms, and adverse events as primary outcomes.4 Three trials met the criteria, randomising 153 participants, and "only one trial had low or unclear risk of bias across all domains and outcome measures".4 Two trials reported serum B12 and the review grades that evidence as low "due to serious imprecision"; adverse-event evidence is graded very low.4 One trial reported no treatment-related adverse events in either group, and one reported that 2 of 30 participants (6.7%) in the oral group left early because of adverse events.4 The authors conclude that "low quality evidence shows oral and IM vitamin B12 having similar effects in terms of normalising serum vitamin B12 levels, but oral treatment costs less", and call for trials with better randomisation and blinding and more participants.4 The record lists the publication type "Research Support, Non-U.S. Gov't" and conflict-of-interest entries of "none known" for all six authors; it states no sponsor otherwise.4
Deeper analysis: Kuzminski and colleagues' randomised trial
Kuzminski and colleagues (Bassett Healthcare, Cooperstown, New York, with co-authors Allen, Stabler and Lindenbaum) reported the trial in Blood in 1998.5 Thirty-eight newly diagnosed cobalamin-deficient patients were randomised to 1 mg intramuscular cyanocobalamin on days 1, 3, 7, 10, 14, 21, 30, 60 and 90, or 2 mg orally daily for 120 days.5 Five patients were later found to have folate deficiency, leaving 18 evaluable patients in the oral group and 15 in the parenteral group, so analyses rest on 33 of the 38 randomised.5 At 4 months, mean methylmalonic acid was 169 nmol/L in the oral group and 265 nmol/L in the parenteral group, and mean homocysteine 10.6 and 12.2 micromol/L.5 The authors report that the higher serum cobalamin and lower methylmalonic acid levels in the oral group were significant, and conclude that 2 mg orally daily "was as effective as 1 mg administered intramuscularly on a monthly basis and may be superior".5 The PubMed record carries no funding statement, author disclosures or limitations section, so none can be quoted.5
Deeper analysis: Eussen and colleagues' dose-finding trial
Eussen and colleagues (Division of Human Nutrition, Wageningen University, the Netherlands) reported the trial in Archives of Internal Medicine in 2005.6 Daily doses of 647 to 1032 μg were associated with 80% to 90% of the estimated maximum reduction.6 The authors conclude that the lowest oral dose required to normalise mild deficiency is "more than 200 times greater than the recommended dietary allowance, which is approximately 3 mug daily".6 The PubMed record lists the publication type "Research Support, Non-U.S. Gov't" and gives no named funder, author disclosures, adverse-event data or stated limitations.6
Deeper analysis: the HOME metformin trial
de Jager and colleagues (Academic Medical Center, Amsterdam, and Dutch hospitals) reported the trial in the BMJ in 2010; it tested metformin, not vitamin B12.9 A total of 196 patients were randomised to metformin and 194 to placebo, and 277 (72%) were still taking treatment at the end; 46 (30 metformin, 16 placebo) stopped because of adverse effects.9 Over the trial, vitamin B12 fell by 89.8 pmol/l (−19%) from baseline with metformin and was unchanged (0%, 95% CI −3% to 4%) with placebo.9 The hazard ratio for developing vitamin B12 deficiency (below 150 pmol/l) on metformin was 5.5 (95% CI 1.6 to 19.1; P=0.01).9 The homocysteine difference between groups was a 5% increase with metformin (95% CI −1% to 11%; P=0.091).9 The authors state that they "measured only total vitamin B-12 levels and not levels of holotranscobalamin II or methylmalonic acid", and that all participants received frequent dietary counselling, which may have attenuated the effect of metformin.9 Funding came from grants from Altana, Lifescan, Merck Santé, Merck Sharp & Dohme and Novo Nordisk, and the statement says the sponsors had no role in design, conduct, analysis or the manuscript; the authors' competing-interest statement lists financial support for the submitted work from Merck Sharp & Dohme.9 One author's listed affiliation is Clinical Research and Development, Merck Netherlands, Amsterdam.9
Doses reported in studies and on labels
| Source | Who and route | Dose and schedule reported | Length and comparator |
|---|---|---|---|
| US cyanocobalamin injection label1 | Pernicious anemia, intramuscular or deep subcutaneous injection | 100 mcg daily for 6 or 7 days, then the same amount on alternate days for seven doses, then every 3 to 4 days for another 2 to 3 weeks, then 100 mcg monthly for life | Label regimen; no comparator |
| UK hydroxocobalamin 1 mg/mL summary of product characteristics3 | Pernicious anaemia and other macrocytic anaemias without neurological involvement, intramuscular | Initially 250 to 1000 micrograms on alternate days for one or two weeks, then 250 micrograms weekly until the blood count is normal; maintenance 1000 micrograms every two to three months | Label regimen; no comparator |
| Kuzminski and colleagues, Blood 19985 | 38 randomised cobalamin-deficient patients; oral against intramuscular | 2 mg oral daily against 1 mg intramuscular on days 1, 3, 7, 10, 14, 21, 30, 60 and 90 | 120 days oral against intramuscular comparator |
| Eussen and colleagues, Archives of Internal Medicine 20056 | 120 older people with mild B12 deficiency; oral cyanocobalamin | Daily 2.5, 100, 250, 500 and 1000 μg | 16 weeks; five oral dose groups, no placebo or injection group named in the record |
| OB12 trial, BMJ Open 20207 | 283 patients aged 65 or older with B12 deficiency; oral against intramuscular | Oral 1 mg/day in weeks 1 to 8, then 1 mg/week; intramuscular 1 mg on alternate days in weeks 1 to 2, 1 mg/week in weeks 3 to 8, then 1 mg/month | 52 weeks, oral against intramuscular comparator |
Side effects reported
The US cyanocobalamin label lists adverse reactions by system: anaphylactic shock and death with parenteral use; pulmonary edema and congestive heart failure early in treatment and peripheral vascular thrombosis; polycythemia vera; "mild transient diarrhea"; itching and transitory exanthema; and a feeling of swelling of the entire body.1 The label lists sensitivity to cobalt and/or vitamin B12 as a contraindication, and states that patients with early Leber's disease who were treated with cyanocobalamin suffered severe and swift optic atrophy.1 The label states that hypokalemia and sudden death may occur in severe megaloblastic anemia that is treated intensely.1 The UK summary lists reactions with frequency "Not Known", including reactive thrombocytosis in the first weeks in megaloblastic anaemia, hypersensitivity reactions, initial hypokalaemia with secondary arrhythmias, headache, paraesthesia, tremor, nausea, vomiting, diarrhoea and injection site reactions.3 The summary states that "there are no modern clinical studies available that can be used to determine the frequency of undesirable effects".3 The Linus Pauling Institute reports no toxic or adverse effects associated with large intakes of vitamin B12 from food or supplements in healthy people and that no tolerable upper intake level has been set by the US Food and Nutrition Board.2 The same page notes that some have raised concern over potential toxicity of high-dose cyanocobalamin supplements in people with impaired kidney function.2
Interactions reported
The US label states that colchicine, para-aminosalicylic acid and heavy alcohol intake for longer than 2 weeks may produce malabsorption of vitamin B12.1 The Linus Pauling Institute states that nitrous oxide oxidises and inactivates vitamin B12, and that long-term proton-pump inhibitor use has been found to decrease blood vitamin B12 concentrations, with deficiency not generally developing until after at least two to three years of continuous therapy.2 It adds that it is not clear whether long-term use of H2-receptor antagonists could cause overt vitamin B12 deficiency.2 In the HOME trial, metformin lowered vitamin B12 against placebo over 4.3 years in people with type 2 diabetes treated with insulin.9
Bloodwork and markers
Sources in this part
The app lists serum B12, homocysteine, complete blood count and potassium as markers to monitor. The US label's laboratory-tests section lists hematocrit, reticulocyte count, vitamin B12, folate and iron levels before treatment, and states that serum potassium must be observed closely in the first 48 hours of initial treatment of pernicious anemia.1 The UK summary states that cardiac arrhythmias secondary to hypokalaemia during initial therapy have been reported, and that regular monitoring of the blood is recommended.3 The US label states that most antibiotics, methotrexate and pyrimethamine invalidate folic acid and vitamin B12 diagnostic blood assays.1 In the HOME trial, homocysteine rose by 3.26 μmol/l with metformin, and by 1.60 μmol/l with placebo, from baseline over 4.3 years.9
Regulatory and anti-doping status
Sources in this part
The UK hydroxocobalamin 1 mg/mL product in the emc has the marketing authorisation number PL 12762/0008, with 18 August 1997 given as the date of first authorisation/renewal of the authorisation.3 The Linus Pauling Institute states that cyanocobalamin and hydroxocobalamin are available by prescription in an injectable form to treat pernicious anemia.2 The 2026 WADA Prohibited List text contains no entry naming vitamin B12, cobalamin or cyanocobalamin; it names cobalt as an example under hypoxia-inducible factor activating agents.10
Storage and handling
Sources in this part
What is not known
No half-life figure could be quoted from the sources read: the US label, the UK summary of product characteristics and the Linus Pauling Institute page give none, and the 1963 Nature record on the biological half-life of vitamin B12 in plasma had no summary text to quote.1,3,2 The app's 144-hour half-life therefore has no matching figure from the sources read. The Cochrane review reports that no trial of oral against intramuscular vitamin B12 reported clinical signs and symptoms, quality of life or acceptability, and its serum B12 evidence is low quality.4 A search of PubMed and ClinicalTrials.gov for oral and intramuscular vitamin B12 trials returned the records cited above; no comparison of methylcobalamin with cyanocobalamin was read for this reference.
Frequently asked questions
What is the half-life of vitamin B12?
How long does injected vitamin B12 take to reach its peak?
The US cyanocobalamin label states that the plasma level reaches its peak within 1 hour after intramuscular injection, and the app lists about 1 hour.1
What is the bioavailability of vitamin B12?
Is vitamin B12 banned by WADA?
The 2026 WADA Prohibited List text contains no entry naming vitamin B12, cobalamin or cyanocobalamin.10
Is injectable vitamin B12 a prescription medicine?
The Linus Pauling Institute states that cyanocobalamin and hydroxocobalamin are available by prescription in an injectable form to treat pernicious anemia.2
Is oral vitamin B12 as effective as injected vitamin B12?
The Cochrane review concludes that low-quality evidence shows oral and intramuscular vitamin B12 having similar effects on normalising serum vitamin B12 levels, from three trials of 153 participants.4 In the OB12 trial of 283 people aged 65 or older, 73.6% in the oral arm and 80.4% in the intramuscular arm had normal B12 at week 52, and the pre-set non-inferiority conditions were not met over the full follow-up.7
Does metformin lower vitamin B12?
In the HOME randomised trial of 390 people with type 2 diabetes treated with insulin, vitamin B12 was 19% lower with metformin than with placebo over 4.3 years (95% CI −24% to −14%).9
Is hydroxocobalamin retained longer than cyanocobalamin?
The UK summary of product characteristics states that hydroxocobalamin is better retained than cyanocobalamin, with 90% of a 100 microgram dose and 30% of a 1000 microgram dose retained.3
Guides, tools and comparisons
References
- Vitruvias Therapeutics (manufacturer); Henry Schein, Inc. (repackager). Cyanocobalamin Injection, USP 1000 mcg/mL. US label, DailyMed record, version 3, 2026. DailyMed label
- Linus Pauling Institute, Oregon State University. Vitamin B12. Micronutrient Information Center. Linus Pauling Institute
- ADVANZ Pharma. Hydroxocobalamin 1mg/ml Solution for Injection. Summary of Product Characteristics, emc, updated 27 January 2025. UK SmPC (emc)
- Wang H, Li L, Qin LL, Song Y, Vidal-Alaball J, Liu TH. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency. Cochrane Database Syst Rev 2018. PMID 29543316
- Kuzminski AM, Del Giacco EJ, Allen RH, Stabler SP, Lindenbaum J. Effective treatment of cobalamin deficiency with oral cobalamin. Blood 1998. PMID 9694707
- Eussen SJ, de Groot LC, Clarke R, Schneede J, Ueland PM, Hoefnagels WH, van Staveren WA. Oral cyanocobalamin supplementation in older people with vitamin B12 deficiency: a dose-finding trial. Arch Intern Med 2005. PMID 15911731
- Sanz-Cuesta T, Escortell-Mayor E, Cura-Gonzalez I, et al. Oral versus intramuscular administration of vitamin B12 for vitamin B12 deficiency in primary care: a pragmatic, randomised, non-inferiority clinical trial (OB12). BMJ Open 2020. PMID 32819927
- ClinicalTrials.gov. NCT01476007. Oral/Intramuscular B12 to Treat Cobalamin Deficiency (OB12). Gerencia de Atención Primaria, Madrid. NCT01476007
- de Jager J, Kooy A, Lehert P, et al. Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ 2010. PMID 20488910
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list